Simultaneous estimation of paclitaxel and bortezomib via LC-MS/MS: pharmaceutical and pharmacokinetic applications.
Nanomedicine (Lond)
; : 1-16, 2024 Aug 08.
Article
em En
| MEDLINE
| ID: mdl-39115873
ABSTRACT
Aim & Objective:
This study evaluates the potential of combining paclitaxel (PTX) and bortezomib (BTZ) for breast cancer therapy. Materials &Methods:
The nanoformulation was optimized via Box-Behnken Design (BBD), with method validation adhering to US-FDA guidelines.Results:
Multiple reaction monitoring transitions for PTX, BTZ and internal standard were m/z 855.80â286.60, 366.80â226.00 and 179.80â110.00, respectively. Elution done on C18 Luna column with 0.1% FA in MeOH10 mM ammonium acetate. The size of nanoformulation was 133.9 ± 1.97 nm, PDI 0.19 ± 0.01 and zeta potential -19.20 ± 1.36 mV. Pharmacokinetics showed higher Cmax for PTX-BTZ-NE (313.75 ± 10.71 ng/ml PTX, 11.92 ± 0.53 ng/ml BTZ) versus free PTX-BTZ (104 ± 13.06 ng/ml PTX, 1.9 ± 0.08 ng/ml BTZ).Conclusion:
Future findings will contribute to the treatment of breast cancer using PTX and BTZ.
[Box see text].
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Índia